A persistent, often progressive, lung disease, COPD results from chronic inflammation that leads to structural changes ...

Healthcare decision-makers are facing significant challenges that will intensify in the coming years as they work to address ...

Novartis NVS announced that the Committee for Medicinal Products for Human Use (“CHMP”) of the European Medicines Agency (EMA ...

Terns Pharmaceuticals' (TERN) stock has risen somewhat due to some optimism around its early-stage clinical programs ...

The Global Non-Small Cell Lung Carcinoma (NSCLC) Market is on the brink of an extraordinary transformation, with market ...

The remarkable surge in the Intratumoral Cancer Therapies market is primarily attributed to the favorable regulatory ...

With Friday’s ruling by New Jersey District Judge Zahid Quraishi, Novartis joins a growing list of pharmaceutical companies ...

An interim analysis from a long-term open-label extension study has underlined the clinical efficacy and safety of ...

BP’s program includes a novel PSMA-binding molecule that may be a potential next-generation radioligand therapy (RLT) for prostate cancer and is currently being studied in two investigator-initiated ...

Throughout the month of October, Shanghai has been a hub of various activities aimed at raising awareness about breast cancer ...

Were it not for his name being associated with a wing of the Bryan West Campus, there virtually would be no visible remnants ...

Novartis' Kisqali receives a positive recommendation from EMA's CHMP for adjuvant treatment of early breast cancer, showing a ...